Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany

Background: Sacituzumab govitecan has been recently approved by the USFDA and EMA for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). We report real-world safety and effectiveness in patients with mTNBC receiving sacituzumab govitecan treatment at a breast cancer cen...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Mattea Reinisch, Simona Bruzas, Jennifer Spoenlein, Satyendra Shenoy, Alexander Traut, Hakima Harrach, Ouafaa Chiari, Efsthatia Cremer, Beyhan Ataseven, Lars Gubelt, Sherko Kuemmel
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	SAGE Publishing 2023-09-01
Saila:	Therapeutic Advances in Medical Oncology
Sarrera elektronikoa:	https://doi.org/10.1177/17588359231200454
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!